News

In a quiet corner of Glasgow’s East End, a radical public health experiment is underway. For the first time in the United ...
It is unclear how the Trump administration will consider affordability when reviewing a drug, as prices are usually ...
Capricor Therapeutics (CAPR) on Friday said the U.S. Food and Drug Administration (FDA) has refused to approve its lead cell ...
Makary, a surgical oncologist tapped by President Trump to serve as the the 27th FDA chief, joined NewsNation on Thursday to ...
The FDA has rejected Capricor Therapeutics’ filing for approval of a Duchenne muscular dystrophy (DMD) cell therapy, raising ...
Happy Friday. Today, we talk about the stem cell fire sale at CIRM, and about the FDA’s move to release a limited batch of ...
The U.S. Food and Drug Administration has published more than 200 complete response letters, or decision letters, sent as ...
Police and fire responded to a neighborhood "in reference to multiple individuals experiencing overdose symptoms".
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.
FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...